Granulomatous disease, chronic, autosomal recessive, 5

disease

On this page

Also known as CGD5chronic granulomatous disease 5, autosomal recessiveGranulomatous Disease, Chronic, Due to Cybc1 Deficiency

Summary

Granulomatous disease, chronic, autosomal recessive, 5 (MONDO:0030066) is a disease caused by CYBC1 (GenCC Strong), with 1 cohort gene.

At a glance

Causal gene: CYBC1 (GenCC Strong)
Cohort genes: 1
ClinVar variants: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	granulomatous disease, chronic, autosomal recessive, 5
Mondo ID	MONDO:0030066
OMIM	618935
DOID	DOID:0070368
UMLS	C5394542
MedGen	1710326
GARD	0016395
Is cancer (heuristic)	no

Also known as: CGD5 · chronic granulomatous disease 5, autosomal recessive · GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 5 · granulomatous disease, chronic, autosomal recessive, 5 · Granulomatous Disease, Chronic, Due to Cybc1 Deficiency

Data availability: 5 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › chronic granulomatous disease › granulomatous disease, chronic, autosomal recessive, 5

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

3 uncertain significance, 1 conflicting classifications of pathogenicity, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
932315	NM_001033046.4(CYBC1):c.6C>G (p.Tyr2Ter)	CYBC1	Pathogenic	no assertion criteria provided
1682695	NM_001033046.4(CYBC1):c.444-1G>C	CYBC1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
3390942	NM_001033046.4(CYBC1):c.361G>A (p.Gly121Arg)	CYBC1	Uncertain significance	criteria provided, single submitter
4847006	NM_001033046.4(CYBC1):c.454G>A (p.Ala152Thr)	CYBC1	Uncertain significance	criteria provided, single submitter
932314	NM_001033046.4(CYBC1):c.127G>A (p.Asp43Asn)	CYBC1	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 2 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CYBC1	Strong	Autosomal recessive	granulomatous disease, chronic, autosomal recessive, 5	2

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CYBC1	Orphanet:379	Chronic granulomatous disease

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CYBC1	HGNC:28672	ENSG00000178927	Q9BQA9	Cytochrome b-245 chaperone 1	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CYBC1	Cytochrome b-245 chaperone 1	Functions as a chaperone necessary for a stable expression of the CYBA and CYBB subunits of the cytochrome b-245 heterodimer.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CYBC1	Other/Unknown	no		Cybc1

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
blood	1
granulocyte	1
spleen	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CYBC1	267	ubiquitous	marker	granulocyte, spleen, blood

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CYBC1	645

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CYBC1	Q9BQA9	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
respiratory burst after phagocytosis	1	4213.0×	5e-04	CYBC1
innate immune response	1	33.6×	0.030	CYBC1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CYBC1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	CYBC1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CYBC1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Cohort genes: CYBC1